| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/31/2003 | WO2003062276A2 Multimers of receptor-binding ligands |
| 07/31/2003 | WO2003062275A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | WO2003062262A2 Modulation of heat-shock-protein-based immunotherapies |
| 07/31/2003 | WO2003062252A1 Edg receptor agonists |
| 07/31/2003 | WO2003062248A2 N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| 07/31/2003 | WO2003062246A1 2-thia-1,6,8-triaza-naphtalene-2,2-dioxides as cdk inhibitors |
| 07/31/2003 | WO2003062242A1 Biocidal compounds and their preparation |
| 07/31/2003 | WO2003062241A1 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
| 07/31/2003 | WO2003062240A1 Pteridine derivatives, method for the production thereof, and use thereof |
| 07/31/2003 | WO2003062236A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
| 07/31/2003 | WO2003062227A1 Rho-kinase inhibitors |
| 07/31/2003 | WO2003062225A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 07/31/2003 | WO2003062220A1 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives |
| 07/31/2003 | WO2003062215A1 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| 07/31/2003 | WO2003062209A2 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin |
| 07/31/2003 | WO2003062191A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | WO2003062190A1 Compounds for modulating cell proliferation |
| 07/31/2003 | WO2003062189A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | WO2003061713A1 Nsaid-containing topical formulations that demonstrate chemopreventive activity |
| 07/31/2003 | WO2003061710A1 AGENT CONTROLLING THE APOPTOSIS INDUCTION BY p73 |
| 07/31/2003 | WO2003061697A1 Preventives/remedies for cancer |
| 07/31/2003 | WO2003061696A2 Systems and methods for photodynamic therapy |
| 07/31/2003 | WO2003061684A2 Tumour treatment compositions comprising hsp70 and tumour necrosis factor |
| 07/31/2003 | WO2003061653A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | WO2003061652A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | WO2003061634A1 Sustained release pharmaceutical composition |
| 07/31/2003 | WO2003061626A1 Polymeric gel system for the controlled delivery of codrugs |
| 07/31/2003 | WO2003061621A2 Dermal application system for aminolevulinic acid-derivatives |
| 07/31/2003 | WO2003061593A2 Novel targeted compositions for diagnostic and therapeutic use |
| 07/31/2003 | WO2003061589A2 Methods for treating diseases or conditions with peptide constructs |
| 07/31/2003 | WO2003061573A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo |
| 07/31/2003 | WO2003061571A2 Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
| 07/31/2003 | WO2003061566A2 Anti-cancer combination and use thereof |
| 07/31/2003 | WO2003061564A2 Gene expression profiles in liver disease |
| 07/31/2003 | WO2003061560A2 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 07/31/2003 | WO2003045971A3 Solvates of 3.beta., 28-diacetoxy-18-oxo-19, 20, 21, 29, 30-pentanorlupan-22-oic acid, processes for their preparation and pharmaceutical compositions thereof |
| 07/31/2003 | WO2003045901A3 Guanidine derivatives |
| 07/31/2003 | WO2003041649A3 Cyanoalkylamino derivatives as protease inhibitors |
| 07/31/2003 | WO2003039460A3 Mitotic kinesin inhibitors |
| 07/31/2003 | WO2003037269A3 Di-, tri,- and tetra-peptides having antiangiogenic activity |
| 07/31/2003 | WO2003037253A3 Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616 |
| 07/31/2003 | WO2003035679A3 Molecules |
| 07/31/2003 | WO2003032911A3 Anti-angiogenic and cytotoxic fused pyrimidines |
| 07/31/2003 | WO2003028696A3 Compositions for delivery of drug combinations |
| 07/31/2003 | WO2003020702A9 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| 07/31/2003 | WO2003018545B1 24-sulfur-substituted analogs of 1α,25-dihydroxy vitamin d¿3? |
| 07/31/2003 | WO2003015825A3 Conjugate |
| 07/31/2003 | WO2003014702A3 Uses of mammalian cytokine; related reagents |
| 07/31/2003 | WO2003010139A3 Antisense modulation of hormone-sensitive lipase expression |
| 07/31/2003 | WO2003008578A3 Reagents and methods for identifying gene targets for treating cancer |
| 07/31/2003 | WO2003006495A3 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 07/31/2003 | WO2003002596A3 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 07/31/2003 | WO2003000024A3 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 07/31/2003 | WO2003000023A3 Method of treating hyperproliferative diseases using active vitamin d analogues |
| 07/31/2003 | WO2002101005A3 A g-protein coupled receptor and uses therefor |
| 07/31/2003 | WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 07/31/2003 | WO2002099042A3 Cads as modifiers of the p53 pathway and methods of use |
| 07/31/2003 | WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 07/31/2003 | WO2002068421A3 Tricyclic compounds and their analogs as inhibitors of cytokine signaling |
| 07/31/2003 | WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| 07/31/2003 | WO2002060464A3 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use |
| 07/31/2003 | WO2002043772A3 Water-soluble polymer conjugates of triazine derivatives |
| 07/31/2003 | WO2002039885A3 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 07/31/2003 | WO2002030863A3 Ether compounds and compositions for cholesterol management and related uses |
| 07/31/2003 | WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 07/31/2003 | WO2002024909A3 Receptor nucleic acids and polypeptides |
| 07/31/2003 | WO2002024897A3 Conditionally replicating viral vectors and their use |
| 07/31/2003 | WO2002020500A3 Materials and methods to potentiate cancer treatment |
| 07/31/2003 | WO2002018361A3 Compounds having activity as inhibitors of cytochrome p450rai |
| 07/31/2003 | WO2002015895A3 Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| 07/31/2003 | WO2002012286A3 Stress proteins and peptides and methods of use thereof |
| 07/31/2003 | WO2002004010A3 Inhibition of tumor growth by a nematode anticoagulant protein |
| 07/31/2003 | WO2001095942A3 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 07/31/2003 | WO2001062298A9 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 07/31/2003 | WO2001034566A3 Protease inhibitors |
| 07/31/2003 | US20030144523 Epothilone derivatives, method for producing same and their pharmaceutical use |
| 07/31/2003 | US20030144509 Prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. |
| 07/31/2003 | US20030144507 Sulfonamide-containing heterocyclic compounds |
| 07/31/2003 | US20030144506 Formula 1 are useful in treating abnormal cell growth in mammals by administering pharmaceutical compositions. |
| 07/31/2003 | US20030144502 Induce apoptosis; anticancer agents |
| 07/31/2003 | US20030144492 Anticancer agents; central nervous system disorders; antiinflammatory agents |
| 07/31/2003 | US20030144482 Diagnosis of skin cancer; vaccine |
| 07/31/2003 | US20030144474 T cell receptor and a biologically active polypeptide with different recognition biding sites connected by a peptide linker; designed to redirect the immune system against various diseases |
| 07/31/2003 | US20030144360 Synthetic bile acid receptor/ farnesoid x-activated receptor (bar/fxr) ligands agn 29 and agn 31 used as anticholesterol agents |
| 07/31/2003 | US20030144350 Modulating fatty acid or triglyceride accumulation by cells; treating obesity and metabolic disorders |
| 07/31/2003 | US20030144346 Methods and compositions for regulation of 5-alpha reductase activity |
| 07/31/2003 | US20030144344 Use as anti-tumor agents; examples of solvents are N-methyl-2-pyrrolidone and acetonitrile |
| 07/31/2003 | US20030144337 Pyrazole-derived kinase inhibitors and uses thereof |
| 07/31/2003 | US20030144331 p53 inhibitors and therapeutic use of the same |
| 07/31/2003 | US20030144330 Peroxidase proliferator activated receptor (PPAR) gamma agonists for playing key role in inducing growth arrest by terminal differentiation of actively proliferating PPAR gamma-expressing cells, particularly transformed adipose cells |
| 07/31/2003 | US20030144329 N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases |
| 07/31/2003 | US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/31/2003 | US20030144321 Antitumor agents |
| 07/31/2003 | US20030144313 Non-steroidal, tetracylic compounds for estrogen-related treatments |
| 07/31/2003 | US20030144312 Coadministering a dose of anti-tumor agent and an opioid inhibitor of ATP-binding cassette (ABC) drug transporter protein to increase the concentration of the antitumor agent in the cancer cell; potentiation; crosses blood-brain barrier |
| 07/31/2003 | US20030144311 Propanoic acid derivatives as intergrin receptor antagonists |
| 07/31/2003 | US20030144309 Inhibitors of Src and other protein kinases |
| 07/31/2003 | US20030144304 Novel hexacyclic compounds |
| 07/31/2003 | US20030144303 Aminopyrimidine and aminopyridine anti-inflammation agents |
| 07/31/2003 | US20030144302 Process for making substituted pyrazoles |